Table 1 Patient demographics and baseline characteristics
Baseline characteristic | Study 1 | Study 2a | ||
|---|---|---|---|---|
| Â | V930 DNA-EP | V930 DNA-EP | V932 Ad | V932 Ad |
|  | 0.25 mg | 2.5 mg | 0.5 × 109vg/injection | 0.5 × 1011vg/injection |
| Â | (n=6) | (n=22) | (n=6) | (n=5) |
Age, years (mean ± SD) | 66.8 ± 9.2 | 58.6 ± 15.9 | 58.8 ± 12.9 | 54.4 ± 8.6 |
Gender, n (%) | Â | Â | Â | Â |
 Male | 2 (33) | 8 (36) | 2 (33) | 4 (80) |
 Female | 4 (67) | 14 (64) | 4 (67) | 1 (20) |
Race, n (%) | Â | Â | Â | Â |
 White | 6 (100) | 21 (96) | 5 (83) | 5 (100) |
 Other | 0 | 1 (4.5) | 1 (16.7) | 0 |
KPS, n (%) | Â | Â | Â | Â |
 100 | 6 (100) | 17 (77) | 6 (100) | 5 (100) |
 90 | 0 | 5 (23) | 0 | 0 |
Tumor diagnosis, n (%) | Â | Â | Â | Â |
 Adenocarcinoma NOS | 1 (17) | 1 (5) | 0 | 0 |
 Breast cancer | 0 | 7 (32) | 3 (50) | 0 |
 Colorectal cancer | 4 (67) | 6 (27) | 1 (17) | 1 (20) |
 Non-small cell lung cancer | 1 (17) | 5 (23) | 2 (33) | 1 (20) |
 Ovarian cancer | 0 | 1 (5) | 0 | 0 |
 Pancreatic cancer | 0 | 1 (5) | 0 | 0 |
 Squamous cell carcinoma | 0 | 1 (5) | 0 | 0 |
 NOS | 0 | 0 | 0 | 1 (20) |
 Renal cancer | 0 | 0 | 0 | 2 (40) |
 Bladder cancer | 0 | 0 | 0 | 1 (20) |
Prior lines of chemotherapy, n (%) | Â | Â | Â | Â |
 0 | 0 | 0 | 0 | 1 (20) |
 1 | 6 (100) | 11 (50) | 2 (33) | 1 (20) |
 2 | 0 | 5 (23) | 3 (50) | 1 (20) |
 ≥3 | 0 | 6 (27) | 1 (17) | 2 (40) |
Stage IV cancer | 0 (0) | 11 (50) | 4 (67) | 3 (60) |